Thurston Springer Miller Herd & Titak Inc. Takes $153,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 9,407 shares of the company’s stock, valued at approximately $153,000.

Other large investors have also made changes to their positions in the company. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter worth about $30,000. GAMMA Investing LLC raised its position in Teva Pharmaceutical Industries by 105.7% in the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock worth $55,000 after purchasing an additional 1,741 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in Teva Pharmaceutical Industries in the first quarter worth about $54,000. Finally, Blue Trust Inc. raised its position in Teva Pharmaceutical Industries by 92.3% in the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock worth $46,000 after purchasing an additional 2,180 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on TEVA. Jefferies Financial Group increased their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $18.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the transaction, the chief accounting officer now directly owns 17,814 shares of the company’s stock, valued at $299,275.20. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CAO Amir Weiss sold 15,500 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the transaction, the chief accounting officer now directly owns 17,814 shares of the company’s stock, valued at $299,275.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares in the company, valued at $777,285. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 574,256 shares of company stock valued at $9,776,999. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded up $0.23 during mid-day trading on Tuesday, hitting $16.91. 10,189,324 shares of the company traded hands, compared to its average volume of 10,453,374. Teva Pharmaceutical Industries Limited has a one year low of $8.06 and a one year high of $18.02. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.52. The business has a 50-day moving average of $16.79 and a 200 day moving average of $14.84. The stock has a market capitalization of $19.15 billion, a price-to-earnings ratio of -41.23, a PEG ratio of 1.49 and a beta of 0.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The business had revenue of $3.82 billion during the quarter, compared to the consensus estimate of $3.70 billion. As a group, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.35 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.